SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its exceptionally active and dedicated community, which is relentlessly building a permissionless brand with tangible real-world products like Kendu Energy and Kendu Spice. The community emphasizes KENDU's growing IRL presence and decentralized business initiatives across multiple chains, fostering strong conviction in its long-term potential. Despite broader market conditions, sentiment remains overwhelmingly bullish, viewing KENDU as a resilient and unavoidable force poised for significant growth.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is actively trending as community sentiment appears divided, with many anticipating a significant rally and 'altseason' following the conclusion of recent tax loss selling, hoping for substantial price increases. Conversely, a vocal group views current movements as temporary and predicts further declines, dismissing its long-term potential as a 'shitcoin' while both sides debate its future trajectory.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending amidst strong community speculation, with many users anticipating a significant upward movement, including hopes of 'dropping a zero' in its price, and a potential 'Alt season' incoming. The community is actively discussing its 'no transaction taxes' mechanic, contributing to an optimistic trading environment, though some express skepticism about its long-term viability.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to its recent announcement of record-high December and Q4 vehicle deliveries for 2025, pushing cumulative sales close to one million units. The community is largely optimistic, highlighting the strong year-over-year growth and the potential for profitability, yet a vocal contingent points to perceived market manipulation as the reason the stock's valuation has not adequately reflected this performance. This fuels debate over its position within the competitive Chinese EV market and expectations for a significant re-rating.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is a trending topic with a polarized community, as supporters emphasize its Japan FSA compliance, ongoing IoT utility development, a completed token supply dilution phase, and anticipation of major news in 2026. Conversely, critics frequently label the project a scam, citing continuous price depreciation and perceived lack of tangible progress.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending amidst strong institutional interest, fueled by the launch of a Grayscale spot ETF and continued whale accumulation anticipating real-world asset adoption and expanding CCIP utility across banks. The community is actively discussing LINK's fundamental role as essential cross-chain infrastructure and its fixed supply, viewing current price levels as a potential accumulation opportunity for future growth.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is actively discussed due to its strategic expansion in the anticoagulation therapy space, highlighted by recent pipeline acquisitions and manufacturing progress for its lead candidate, tecarfarin. Community sentiment focuses on the potential impact of tecarfarin's regulatory designations and a key collaboration for its pivotal trial. However, ongoing concerns about potential dilution and the stock's low float contribute to a volatile trading dynamic.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is trending as a low-float SPAC, currently experiencing a surge in trading volume and retail interest. The community is actively discussing its potential for a parabolic run, drawing comparisons to recent "shell company rippers" and fueling expectations of significant price appreciation. This momentum is part of a broader speculative trend in low-float SPACs, with traders anticipating continued upward movement.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is a major talking point as the stock experiences persistent declines, fueled by end-of-year tax loss harvesting and a high short interest. Investor sentiment is sharply polarized, with bulls emphasizing the company's strong subscriber growth and strategic expansions into new health verticals and international markets as a buying opportunity. Conversely, bears highlight ongoing valuation concerns, intense competition in the GLP-1 weight loss drug market, and alleged market manipulation, despite recent company announcements like a new share buyback program and discussions around distributing Novo Nordisk's newly approved oral Wegovy pill.

Amplify ETF Trust - Amplify Junior Silver Miners ETF

Amplify Junior Silver Miners ETF

SILJ is trending as silver continues its explosive rally to new all-time highs, fueled by structural deficits, robust industrial demand, and macroeconomic concerns over currency debasement. While the ETF has notably lagged silver's "crypto-like" surge, the community is buzzing with anticipation for a significant catch-up rally, driven by historically undervalued ratios and recent institutional interest suggesting junior miners are primed for outperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The market is now looking forward to an executive order from President Trump directing federal agencies to reclassify marijuana as a less dangerous drug.</li><li>A Stocktwits user expressed hopes for Trump signing an executive order as early as Wednesday.</li></ul>Shares of Tilray Brands (TLRY) soared 31% on Tuesday afternoon as the market gears up for a reclassification of Marijuana.Tilray, a producer and distributor of medical and adult-use cannabis, has witnessed volatile trading over the past few days. It closed up 44% on Friday and fell 10% on Monday before rising back again on Tuesday. Shares of the company have gained nearly 79% over the past five days.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TLRY is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/59;" src="data:image/png;base64,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" width="623" height="59" alt="TLRY’s Sentiment Meter and Message Volume as of 1:41 p.m. ET on December 16, 2025 | Source: Stocktwits"><figcaption>TLRY’s Sentiment Meter and Message Volume as of 1:41 p.m. ET on December 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes for Trump signing an executive order directing federal agencies to reclassify marijuana as a less dangerous drug as early as Wednesday. “Is Tomorrow going to be &nbsp;" Weed"nesday ???,” they wrote.<stembedurl>https://www.stocktwits.com/Nomoregambling123/message/639326923</stembedurl>Another believes the stock rising 92% to 115% from current levels is “very doable.” The user sees the stock hitting as high as $28 but added that it is “pure speculation at this point.”<stembedurl>https://www.stocktwits.com/Beto_365/message/639324734</stembedurl><h2 class="st-heading-2">Marijuana Reclassification Hopes</h2>Trump first hinted at reclassifying marijuana as a less dangerous drug in August. On Wednesday, Trump reportedly discussed the plan with House Speaker Mike Johnson, a Republican, in a call that also included marijuana industry executives, Health Secretary Robert F. Kennedy Jr., and CMS chief Mehmet Oz.The president is expected to seek to ease access to the drug through an upcoming executive order that directs federal agencies to pursue reclassification, the Washington Post reported on Thursday, citing unnamed sources.On Friday, CNBC <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-sndl-soar-on-hopes-trump-will-reclassify-marijuana-on-monday/cLICDZhRE8W">reported</a> that an executive order could come as soon as Monday, causing a significant surge in cannabis stocks during the Friday trading session. However, the rally didn't hold on Monday as investors cashed in on the Friday gains.While the executive order didn’t arrive on Monday, Trump said during a Mexican Border Defense medal presentation at the White House in Washington, DC, that he is “strongly” looking at an executive order directing federal agencies to reclassify marijuana/"We are considering that. Because a lot of people want to see it," Trump <a href="https://stocktwits.com/news-articles/markets/equity/cannabis-stocks-lose-their-high-as-profit-taking-kicks-in-despite-trumps-reclassification-talk/cLe4j1YREoD">said</a>. "The reclassification, because it leads to tremendous amounts of research that can’t be done unless you reclassify. So we are looking at that very strongly."<h2 class="st-heading-2">Tilray CEO Echoes Optimism</h2>Tilray CEO Irwin Simon also highlighted in October that the regulatory environment in the industry is “poised for meaningful evolution.”Marijuana remains a Schedule I drug under federal law — the same category as heroin and LSD — a classification reserved for substances deemed to have high abuse potential and no accepted medical use.Trump is expected to classify marijuana as a Schedule III substance, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatments, but can also create risks of physical or psychological dependence.Other Schedule III drugs include Tylenol with codeine, as well as specific steroid and hormone treatments.<h2 class="st-heading-2">Expert Take</h2>According to data from Koyfin, the average price target on Tilray is $16.17, presenting a potential upside of over 18% from current trading levels. Of the nine analysts covering the stock, six rate it a ‘Hold’ while three rate it ‘Buy’ or higher.<a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> is up 19% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-stock-on-track-for-worst-day-in-over-8-months-as-bofa-flags-faster-covid-19-product-errosion/cLeJK4YREpe">Pfizer Stock On-Track For Worst Day In Over 8 Months As BofA Flags Faster Covid-19 Product Erosion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Stock On Track For Near 2-Month High As 'Weednesday' Buzz Builds Around Trump Cannabis Order — Retail Eyes Massive Upside

Tilray, a producer and distributor of medical and adult-use cannabis, has witnessed volatile trading over the past few days.

Equity

Tilray, a producer and distributor of medical and adult-use cannabis, has witnessed volatile trading over the past few days.


<ul class="summary-bullets"><li>The CEO said that the company received 50,000 orders for the pickup trucks incorporating its reintroduced Hemi V8 engine.&nbsp;</li><li>The company is also looking to relaunch the Jeep Cherokee to the end of December, featuring a a hybrid engine.</li><li>Filosa sees hybrid being one of the favorite powertrains in the U.S.</li></ul>Stellantis (STLA) CEO Antonio Filosa said on Thursday that the company envisions ‘highly sustainable’ demand growth with the launch of new engines and vehicle models as he seeks to claw back market share.The CEO said that the company received 50,000 orders for the pickup trucks incorporating its reintroduced Hemi V8 engine.Stellantis had previously phased out the engine and reintroduced it in pickup trucks in the third quarter (Q3). The CEO said at the Goldman Sachs Industrial &amp; Auto Conference on Thursday that the company delivered 10,000 v8-equipped Hemi engine RAM vehicles in Q3 and expects to ship another 20,000 in the fourth quarter.<h2 class="st-heading-2">Other Launches</h2>The company is also looking to relaunch the Jeep Cherokee by the end of December, featuring &nbsp;a hybrid engine. It is also eyeing the launch of a new Dodge Charger with an internal combustion engine.“So we are launching hybrid because we truly believe that hybrid is going to be one of the favorite powertrains in the U.S.,” Filosa said on Thursday. The company expects its sequence of product launches to spark volume growth that is “highly sustainable and progressively better quarter by quarter.”“Through the end of November, we are on track on our guidance,” Filosa said about the company’s profitability expectations. The CEO also highlighted that the company’s execution is improving with more product launches following promised timelines.<h2 class="st-heading-2">Tariff Impact</h2>The CEO highlighted that U.S. tariffs are getting stable and the company is looking to offset the impact of the Trump administration’s tariffs by onshoring production.In October, Stellantis committed $13 billion to expand its US operations over the next four years. The investment will support the launch of five new vehicles, the company then said.<h2 class="st-heading-2">Filosa Attempts Major Pivot</h2>Stellantis <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-selects-antonio-filosa-as-new-ceo/ch0oL02Rbs3">appointed</a> Filosa as CEO in May after its previous chief executive, Carlos Tavares, stepped down in December 2024.In October, the company reported a 13% growth in Q3 revenue to €37.2 billion ($43.35 billion) owing to a 13% growth in consolidated shipments to 1.3 million units.“As we continue to implement important strategic changes in order to provide our customers with greater freedom of choice, we have seen positive sequential progress and solid year-over-year performance in Q3, marked by the return of top-line growth. This is encouraging and we are continuing to build on these gains,” Filosa then said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">Stellantis</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.The stock is down by 9% this year and by about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pepsico-close-to-striking-settlement-with-activist-giant-elliott-after-4-billion-push-for-change/cLIi4iXREj1">PepsiCo Is Close To Striking A Settlement With Activist Giant Elliott After Its $4B Push For Change</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

New Ram vehicles sit on a Dodge Chrysler-Jeep Ram dealership's lot on October 03, 2023 in Miami, Florida. (Photo by Joe Raedle/Getty Images)

Stellantis CEO Says New Engine, Vehicle Models Will Drive ‘Progressively Better’ Demand 

Filosa said that the company is on track on its full year guidance through the end of November. 

<ul class="summary-bullets"><li>In the three months through the end of September, Li delivered 93,211 vehicles, representing a 39.0% year-over-year decrease.</li><li>Adjusted net loss per American Depositary Share (ADS) was RMB0.36 in Q3, compared to earnings of RMB3.63 per ADS reported in the corresponding quarter of 2024.&nbsp;</li><li>For the fourth quarter, the company expects to deliver between 100,000 and 110,000 vehicles, representing a year-over-year decrease of 37.0% to 30.7%.</li></ul>Li Auto (LI) CEO Xiang Li stated on Wednesday that several challenges impacted the company over the three months through the end of September, including supply chain constraints, product lifecycle challenges, PR challenges, and changing policies, resulting in an unexpected loss.“All these factors have had a negative impact on our operations and deliveries,” he said. In the three months through the end of September, Li <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lixiang.com/news-releases/news-release-details/li-auto-inc-announces-unaudited-third-quarter-2025-financial">delivered</a> 93,211 vehicles, representing a 39.0% year-over-year decrease.<h2 class="st-heading-2">Q3 Earnings</h2>Total revenues in the quarter came in at RMB27.4 billion ($3.87 billion), down 36.2% from RMB42.9 billion in the third quarter of 2024, but above the analyst estimate of RMB26.49 billion.Adjusted net loss per American Depositary Share (ADS) was RMB0.36 in the quarter, compared to earnings of RMB3.63 per ADS reported in the third quarter of 2024. Analysts on average had expected the company to report earnings of RMB0.64 per share.For the fourth quarter, the company expects to deliver between 100,000 and 110,000 vehicles, representing a year-over-year decrease of 37.0% to 30.7%, amid subdued demand and strong competition.Total revenue, meanwhile, is expected to be between RMB26.5 billion and RMB29.2 billion, representing a year-over-year decrease of 40.1% to 34.2%. This is below the analyst estimate of RMB36.99 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/LI">LI shares</a> traded 3% higher at the time of writing on Wednesday morning. On Stocktwits, retail sentiment around LI stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user expressed surprise at the stock rising.<stembedurl>https://stocktwits.com/Kingofsting/message/637515375</stembedurl>Another highlighted that the positive stock reaction reflects how beaten down the shares already were.<stembedurl>https://stocktwits.com/topstockalerts/message/637526362</stembedurl>LI stock is down by 22% this year and by about 14% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/arrowhead-pharmaceuticals-stock-jumps-after-morgan-stanley-hikes-price-target/cL53te9REWo">Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: RMB1= $0.14

Employees adjust new energy vehicles at the workshop of Li Auto Changzhou Manufacturing Base on December 10, 2024 in Changzhou, Jiangsu Province of China. (Photo by Chen Wei/VCG via Getty Images)

Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop

CEO Xiang Li highlighted challenges pertaining to the supply chain and product lifecycle, among others. 

<ul class="summary-bullets"><li>Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said.</li><li>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.&nbsp;</li><li>The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.</li></ul> Novo Nordisk (NVO) on Tuesday said that a mid-stage trial evaluating Amycretin in people with type 2 diabetes yielded positive outcomes in both weight loss and reduction in average blood sugar levels.NVO shares traded 3% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Study Outcomes</h2>Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks, as compared to 2.6% in patients treated with placebo, and demonstrated statistically significant reductions in average blood sugar levels, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html">said</a>.The trial investigated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous Amycretin and once-daily oral amycretin compared with placebo in 448 people with type 2 diabetes inadequately controlled on metformin. About 40% of the study participants also used a class of drugs known as SGLT2 inhibitors to manage their diabetes before joining the study.Amycretin belongs to the class of drugs known as GLP-1s, used to treat diabetes and obesity, similar to Novo’s blockbuster drugs Wegovy and Ozempic. Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said. The common side effects were gastrointestinal, and the vast majority were mild to moderate in severity, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.Chief Scientific Officer Martin Holst Lange noted that this is the first time Amycretin has been evaluated in this population and added that the company is planning to test the GLP-1 compound across multiple indications starting next year.The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.The company said on Monday that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression, and it is subsequently discontinuing them.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by 48% this year and by about 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/autl-stock-soars-pre-market-on-position-recommendation-for-cell-therapy-targeting-cancer-in-uk/cL52LfPREXA">AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes. 

<ul class="summary-bullets"><li>The company’s second-quarter revenue rose 5% to RMB 247.80 billion, compared with analysts’ expectations of RMB 243.2 billion, according to data compiled by Fiscal AI.&nbsp;</li><li>Alibaba said that it was seeing accelerated adoption of its AI products across a broad range of enterprise customers, with a growing focus on value-added applications, including coding assistants.</li><li>The company said that its quick commerce business has substantially improved its unit economics since September.</li></ul>Alibaba Group Holding (BABA) shares rose nearly 4% in premarket trading on Tuesday as investor optimism gathered momentum after the company’s upbeat second-quarter revenue and CEO Eddie Wu’s remarks on robust AI demand accelerating the Cloud Intelligence Group business.“With our significant strategic investments in these areas, our two core businesses of AI + Cloud and consumption continued to deliver strong growth this quarter,” Wu said.He added that Cloud Intelligence Group's revenue was up 34% for the quarter ended September 30, and AI-related product revenue achieved triple-digit year-over-year growth for the ninth consecutive quarter.The company’s second-quarter revenue rose 5% to RMB&nbsp;247.80 billion ($34.89 billion), compared with analysts’ expectations of RMB 243.2 billion, according to data compiled by Fiscal AI.Alibaba’s adjusted net income was RMB 10.35 billion, compared to RMB 36.52 billion in the same quarter of 2024.<h2 class="st-heading-2">BABA CFO View</h2>CFO Toby Xu said that Alibaba’s core businesses continued to deliver revenue growth, with AI revenue contributing to an expanding share of its cloud revenues from external customers, and customer management revenue being up 10%.“We are re-investing our profits and free cash flow for the future, while near-term profitability is expected to fluctuate. Over the past four quarters, we have deployed approximately RMB120 billion in capital expenditure toward AI and cloud infrastructure,” said Xu.Alibaba said that it was seeing accelerated adoption of its AI products across a broad range of enterprise customers, with a growing focus on value-added applications, including coding assistants. “We will continue to invest in anticipation of customer growth and technology innovation, including AI products and services, to increase adoption of AI infrastructure cloud and strengthen our market leadership,” Alibaba said.<h2 class="st-heading-2">E-commerce Growth</h2>Alibaba said its quick commerce business has substantially improved unit economics since September, driven by higher fulfillment logistics efficiency, strong customer retention, and rising average order value.“As part of our strategy to generate synergies between quick commerce and the rest of Alibaba’s ecosystem, we accelerated the onboarding of Tmall brands to our quick commerce channel to expand product offering and meet consumer needs for on-demand delivery,” the company said.Alibaba onboarded offline stores from nearly 3,500 Tmall brands to the quick commerce business as of October 31, 2025.<h2 class="st-heading-2">What Is Retail Thinking?</h2>Alibaba’s ticker was the top third-trending one on Stocktwits. Retail sentiment on Alibaba jumped to ‘bullish’ territory from ‘extremely bearish’ a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/BABA">Shares of Alibaba</a> have gained nearly 90% this year.&nbsp;RMB 1 = $0.14For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amex-gbt-reportedly-mulls-potential-sale/cL52QdHREXS">Amex GBT Reportedly Mulls Potential Sale, Retail Turns Bullish</a>

The Alibaba booth at the 3rd China International Supply Chain Expo, pictured on 18 August 2025. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BABA Stock Rises Pre-Market As AI-Driven Cloud Growth Drives Revenue Beat

CEO Eddie Wu said Cloud Intelligence Group's revenue rose 34% in the quarter ended September 30.

<ul class="summary-bullets"><li>Semaglutide is the active ingredient in Novo’s blockbuster drugs Wegovy and Ozempic.&nbsp;</li><li>The company said it decided to test the drug in Alzheimer’s disease based on real-world evidence and preclinical models.</li><li>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease.</li></ul>Novo Nordisk (NVO) on Monday said that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression.Shares of the company slumped 11% in the pre-market session at the time of writingSemaglutide is the active ingredient in Novo’s blockbuster weight-loss drug Wegovy. The company said that it decided to test the drug in Alzheimer’s based on real-world evidence studies, pre-clinical models, as well as post-hoc analyses from diabetes and obesity trials. The compound, belonging to the category known as GLP-1 drugs, is marketed as Ozempic and Rybelsus for the treatment of type 2 diabetes as well.<h2 class="st-heading-2">Trial Outcomes</h2>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193328/0/en/Novo-Nordisk-A-S-Evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-Alzheimer-s-disease-progression.html">said</a>. The two trials enrolled a total of 3,808 adults and were aimed at evaluating the efficacy and safety of oral Semaglutide compared to placebo on top of standard of care in early-stage symptomatic Alzheimer’s disease.Alzheimer’s is a leading cause of memory loss or dementia. It is a progressive disease where symptoms gradually worsen over time. Semaglutide appears to have a safe and well-tolerated profile in the studies with patients aged 55-85 suffering from mild cognitive impairment or mild dementia due to Alzheimer’s disease, Novo noted.The company said that it is discontinuing the trials. However, the data generated will continue to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, it added. The data from the trials will also be presented at future conferences, the company said.<h2 class="st-heading-2">Semaglutide And Its Many Indications</h2>Semaglutide is Novo's biggest asset. In the nine months through the end of September, the company reported sales of DKK 95.264 billion ($14.721.52 billion) from Ozempic, DKK 16.790 billion from Rybelsus and DKK 57.242 billion from Wegovy, togetherly accounting for about 74% of the company’s overall sales in the period.&nbsp;An approval in Alzheimer’s could have helped the company ramp revenue from the compound as its rivalry with American GLP-1 drugmaker Eli Lilly intensifies.&nbsp;The company’s drop in share price prompted a change in CEO earlier this year and layoffs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 45% this year and by 54% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: DKK1= $0.15

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies

The company said that it is discontinuing the trials.

<ul class="summary-bullets"><li>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.</li><li>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five.</li><li>As per the agency, not all cases automatically qualify for compensation, but instead, each claim will be assessed individually.</li></ul>Four patients taking Novo Nordisk’s (NVO) weight loss drugs have been granted compensation in Denmark after they developed an adverse reaction that affected their eyes.The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://patienterstatningen.dk/presse-og-nyheder/nyheder/2025/nov/de-foerste-patienter-faar-erstatning-for-alvorlig-oejensygdom-efter-wegovy-og-ozempic">said</a> on Friday. If it is proved that the eye disease is to blame for the patients not being able to do their jobs to the same extent as before, they will be entitled to compensation for loss of earning capacity, the authority said.<h2 class="st-heading-2">Cases In Question</h2>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.NAION, or non-arteritic anterior ischemic optic neuropathy, is a medical condition causing sudden, painless vision loss due to a lack of blood flow to the optic nerve. There is no cure for the condition, which can cause blurry or worsening vision, reduced color vision, and optic disc swelling.<h2 class="st-heading-2">Compensation Not Guaranteed</h2>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five. According to the agency, not all cases automatically qualify for compensation; each claim will be assessed individually to determine whether compensation is warranted.“NAION is a serious disease that causes permanent and incurable damage to vision. It is also a very complex case to assess because it is a new medicine and the patients are already in the risk group for getting NAION. Our task is to give patients a thorough and well-thought-out decision," director of Patient Compensation, Karen-Inger Bast, said. &nbsp;The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) considers NAION to be a rare side effect of Wegovy, Ozempic, and Rybelsus.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> traded 1% lower on Friday morning at the time of writing. On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.NVO stock is down 45% this year and by about 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-etfs-hit-record-outflows-average-investor-now-in-the-red/cLPMoktREOm">Bitcoin ETFs Hit Record Monthly Outflows In November – Average Investor Now in the Red, Says Analyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic

The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation said on Friday.

<ul class="summary-bullets"><li>After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified in the patient who died, the FDA said.&nbsp;</li><li>The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma.</li><li>The agency noted that neutralizing antibodies were not reported in clinical trials.</li></ul>The U.S. Food and Drug Administration (FDA) said on Friday that it is investigating the death of a patient treated with Adzynma.Adzynma, a man-made enzyme therapy manufactured by Takeda Pharmaceuticals (TAK), is approved for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman syndrome. It is a rare inherited disorder characterized by a severe deficiency of the ADAMTS13 enzyme.The death of a pediatric cTTP patient appears to be related to Adzynma, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-death-due-neutralizing-antibodies-adamts13-following-adzynma-treatment-congenital">said</a>.<h2 class="st-heading-2">Findings And Further Probe</h2>Before starting Adzynma treatment, the patient had severe allergic reactions to fresh frozen plasma, the FDA noted. After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified.However, the agency also noted that current assays cannot differentiate the neutralizing antibodies to man-made enzyme therapy from the neutralizing antibodies to the body’s own enzymes. The agency also added that it has received other reports of neutralizing antibodies in patients treated with the drug since approval.The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma. The agency noted that neutralizing antibodies were not reported in clinical trials and that the current labeling does not include the risk of serious and fatal outcomes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TAK stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/TAK">TAK stock</a> has gained 8% this year and about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-obesity-drug-patients-granted-compensation-in-denmark-over-rare-eye-disease-linked-to-wegovy-ozempic/cLPMqfwREOY">Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Takeda Pharmaceutical Company, building exterior with company sign, 500 Kendall Street, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 

<ul class="summary-bullets"><li>The outcome was unsurprising as Novo Nordisk Foundation controls 77% of the votes at the Novo Nordisk Annual General Meeting.</li><li>Sorensen said he intends to stay on in the role for a maximum of three years.</li></ul>Novo Nordisk (NVO) said on Friday that Lars Rebien Sørensen, the chair of its dominant shareholder, Novo Nordisk Foundation, has been elected as chair of the Board at the drugmaker, replacing Helge Lund.The outcome was unsurprising as Novo Nordisk Foundation controls 77% of votes at the Novo Nordisk Annual General Meeting through its investment company, Novo Holdings A/S. Sørensen was also previously the CEO of Novo from 2000 to 2016. &nbsp;<h2 class="st-heading-2">The New Chairman</h2>Sørensen, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916459">said</a> that he intends to hold the position only for a period of two to three years. “My mandate is very clear. I have two important tasks together with the Board: First, to support the CEO and the management in its transformation plans to regain its competitive leadership, and second, prepare the way for my successor,” he said.Novo named Mike Doustdar as CEO of the company in August after Lars Fruergaard Jørgensen stepped down in May. Jørgensen decided to step down as per a mutual agreement with the Novo Nordisk board. The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.Sorensen on Friday also said that he is looking to “strengthen the board with some qualifications,” with recent pharma or over-the-counter business experience. “We might see a future where our GLP-1 product is going in this direction,” he said, highlighting the company’s ambitions to make its drugs over-the-counter without prescription.Minority shareholders, including Norway’s sovereign wealth fund and CalSTRS, opposed Sorensen’s appointment. Proxy advisor ISS also urged investors to abstain, citing “limited transparency and accountability to minority shareholders.”<h2 class="st-heading-2">Other appointments</h2>Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.The new appointment comes amid Novo’s intense competition in the weight-loss drug market with its U.S. counterpart, Eli Lilly, and a dramatic board rupture last month, in which disagreements over governance principles between Novo’s board and the foundation prompted more than half of the supervisory board to resign.<a href="https://stocktwits.com/symbol/NVO">Shares of NVO</a> traded 2% lower by Thursday noon. On Stocktwits, retail sentiment around NVO rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism about the stock, citing the price-to-earnings valuation.<stembedurl>https://stocktwits.com/Bassfisher89/message/636229521</stembedurl>Another expressed hopes for the stock’s prospects.<stembedurl>https://stocktwits.com/Natetruu/message/636213210</stembedurl>NVO shares are down by 44% this year and by 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-eyes-reapplication-for-approval-of-muscle-atrophy-therapy-in-2026/cLPQ17HRE4q">Why Did Scholar Rock Soar 26% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Novo Nordisk Brings Back Former CEO To Lead Board

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 

<ul class="summary-bullets"><li>The new plant opened in North Carolina is Toyota’s eleventh in the U.S. and its only battery plant outside Japan.&nbsp;</li><li>The batteries made at the plant will power vehicles including the Camry HEV, Corolla Cross HEV, RAV4 HEV, and a yet-to-be-announced all-electric 3-row BEV.</li><li>The additional $10 billion investment will bring Toyota’s total investment in the U.S. to nearly $60 billion since the carmaker started operations in the country.</li></ul>Japanese automaker Toyota Motor (TM) announced on Wednesday that it will invest up to an additional $10 billion in the U.S. over the next five years, as it seeks to expand its operations in its key market.The additional investment will bring Toyota’s total investment in the U.S. to nearly $60 billion since the carmaker started operations in the country.<h2 class="st-heading-2">New Plant Kick Start</h2>The company on Wednesday also kick-started production at its all-new $14 billion battery plant in Liberty, North Carolina. The plant is Toyota’s eleventh in the U.S. and its only battery plant outside Japan.The 1,850-acre site is expected to create up to 5,100 new jobs and produce 30 GWh annually at full capacity, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://global.toyota/en/newsroom/corporate/43553969.html">stated.</a> It will serve as the development and production hub for lithium-ion batteries needed for Toyota’s electrified vehicles, with 14 battery production lines supporting hybrid electric vehicles (HEVs), battery electric vehicles (BEVs), and plug-in hybrid electric vehicles (PHEVs).The batteries made at the plant will power vehicles including the Camry HEV, Corolla Cross HEV, RAV4 HEV, and a yet-to-be-announced all-electric 3-row BEV. It currently ships HEV modules to both Toyota Kentucky and Mazda Toyota Manufacturing in Alabama, the company said.<h2 class="st-heading-2">Trump’s Push</h2>The investment announcement comes as President Trump is pushing for more investments in the country, including through the imposition of high tariffs on imported vehicles.“Go out and buy a Toyota,” Trump said last month in an address to U.S. troops aboard the USS George Washington at the Yokosuka Naval Base after the Japanese PM informed him that Toyota is planning a $10 billion investment.According to Toyota estimates, the company has sold more than 6.6 million hybrid, plug-in hybrid, fuel cell, and battery electric vehicles in the U.S. since 2000.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TM">TM stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.TM stock is up by 6% this year and by 18% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/uber-coo-says-robotaxi-tech-is-largely-ready-but-hardware-costs-are-still-too-high/cLPICXdREd7">Uber COO Says Robotaxi Tech Is Largely Ready But Hardware Costs Are Still Too High</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Commits Up To $10B Additional Investments In US Over Five Years

The company also kick-started production at its all-new $14 billion battery plant in Liberty, North Carolina, on Wednesday.

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFAX News

DFAXDimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF